Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
RESEARCH TOOLSreports
Total Valuation
BioMark Diagnostics has a market cap or net worth of C$26.36M. The enterprise value is ―.
Market CapC$26.36M
Enterprise Value―
Share Statistics
BioMark Diagnostics has 90,886,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding90,886,230
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioMark Diagnostics’s return on equity (ROE) is 2.34 and return on invested capital (ROIC) is -123.86%.
Return on Equity (ROE)2.34
Return on Assets (ROA)-1.31
Return on Invested Capital (ROIC)-123.86%
Return on Capital Employed (ROCE)8.47
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioMark Diagnostics is -17.91. BioMark Diagnostics’s PEG ratio is -2.64.
PE Ratio-17.91
PS Ratio0.00
PB Ratio-18.63
Price to Fair Value-41.95
Price to FCF-25.38
Price to Operating Cash Flow-23.91
PEG Ratio-2.64
Income Statement
In the last 12 months, BioMark Diagnostics had revenue of 163.22K and earned -1.43M in profits. Earnings per share was -0.02.
Revenue163.22K
Gross Profit163.22K
Operating Income-1.32M
Pretax Income-1.62M
Net Income-1.43M
EBITDA-919.05K
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -855.64K and capital expenditures -3.74K, giving a free cash flow of -859.39K billion.
Operating Cash Flow-855.64K
Free Cash Flow-859.39K
Free Cash Flow per Share>-0.01
Dividends & Yields
BioMark Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.40
52-Week Price Change20.83%
50-Day Moving Average0.28
200-Day Moving Average0.24
Relative Strength Index (RSI)46.78
Average Volume (3m)15.33K
Important Dates
BioMark Diagnostics upcoming earnings date is Jul 9, 2025, TBA Not Confirmed.
Last Earnings DateMar 1, 2025
Next Earnings DateJul 9, 2025
Ex-Dividend Date―
Financial Position
BioMark Diagnostics as a current ratio of 0.16, with Debt / Equity ratio of -49.78%
Current Ratio0.16
Quick Ratio0.16
Debt to Market Cap0.03
Net Debt to EBITDA-0.71
Interest Coverage Ratio-11.43
Taxes
In the past 12 months, BioMark Diagnostics has paid -193.49K in taxes.
Income Tax-193.49K
Effective Tax Rate0.12
Enterprise Valuation
BioMark Diagnostics EV to EBITDA ratio is -28.53, with an EV/FCF ratio of -26.57.
EV to Sales160.65
EV to EBITDA-28.53
EV to Free Cash Flow-26.57
EV to Operating Cash Flow-26.69
Balance Sheet
BioMark Diagnostics has C$88.58K in cash and marketable securities with C$546.53K in debt, giving a net cash position of C$457.95K billion.
Cash & Marketable SecuritiesC$88.58K
Total DebtC$546.53K
Net CashC$457.95K
Net Cash Per Share<C$0.01
Tangible Book Value Per Share>-C$0.01
Margins
Gross margin is -2.31%, with operating margin of -806.71%, and net profit margin of -874.52%.
Gross Margin-2.31%
Operating Margin-806.71%
Pretax Margin-993.06%
Net Profit Margin-874.52%
EBITDA Margin-563.07%
EBIT Margin-803.96%
Analyst Forecast
The average price target for BioMark Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-4.98%
EPS Growth Forecast-13.59%